## RECEIVED

Express Mail Label No. EV 246879918 US Attomey Docket No. 4409.214-US Serial No. 09/772,607

JAN 1 2 2004

**TECH CENTER 1600/2900** 

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Attorney Docket No.: 4409.214-US

Application No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, C.

Confirmation No: 2082

For: Peptide Derivatives

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

- 1. U.S. Patent No. 6,268,343
- 2. U.S. Patent No. 6,458,924

01/08/2004 CCHAU1 00000176 141447 09772607

01 FC:1806 1

180.00 DA

Express Mail Label No. EV 246879918 US Attorney Docket No. 4409.214-US Serial No. 09/772,607

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is (check off either one)

the statement as specified in 37 C.F.R. § 1.97(e)

or

the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: January 2, 2004

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West

Princeton, NJ 08540 (609) 987-5800

Use the following customer number for all correspondence regarding this application

23650
PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 4409.214-US

Serial No. DECENTION TO Be Assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Jonassen et al. JAN 1.2 2004

2 2004 원

(Use several sheets if necessary)

Filing Date January 30, 2001 TO Be TECH GENTER 1600/2900

A FRADENARY	U.S. PATENT DOCUMENTS								
RECEIVE	ח	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		FILING DATE IF APPROPRIATE	
NEOLIVE	1	5,359,030	10/25/94	Ekwuribe					
JAN 1 2 200									
	.		\$ .				· ·	<del></del>	
TECH CENTER 1600	/2900								
	-								
								-	
:	<u></u>		POPRICI	PATENT DOCUMENTS					
		DOCUMENT	TORBIGA	PATENT DOCUMENTS	<u> </u>	T	TRANSLATION		
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
		0 511 600	11/04/92	EPO					
·		WO 93/15750	08/19/93	PCT					
		WO 93/21320	10/28/93	PCT					
				-					
<del></del>							<u> </u>	<u> </u>	
		OTHER DOCUMENTS	(Including Aut	hor, Title, Date, Pert	tinent Page	es, Etc.)	· 		
		Abstract, File 73, Dialog Accession No. 8421240							
		Abstract, F	ile 434, Dia	log Accession No.	1261607	1			
		Abstract, F	ile 434, Dia	log Accession No.	1356551	4			
		Chemical Abstracts, Vol. 123, No. 10, The Abstract No. 122862m							
				. 118, No. 16, Th			-		
							.510)		
<del></del>			·				•		
· · · · ·									
		<del></del>							
								-	
· ·	-		`.					<del>.</del>	
			· · · · · · · · · · · · · · · · · · ·		· .	:	<del></del>		
EXAMINER				DATE CONSIDERED			•		
• • • • • • • • • • • • • • • • • • • •									

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

01	FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTM PATENT AND	MENT OF COMMERCE TRADEMARK OFFICE	Atty. Docket No. 4409.214-US		Serial No. 09/772,607						
511	~ (g)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Jonassen et al.								
JAN 0 2	2004	(Use several sheets if necessary)		Filing Date January 30,	Group 1653							
<b>X</b>			U.S. PATE	NT DOCUMENTS	,							
FRI & FRI	ADEMINER EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
		6,268,343	7/31/01	Ellis	514	325						
RECEIVED		6,458,924	10/1/02	Knudsen et al.	530	324						
Ş												
CE	1 2 2											
RE	JAN 1 2 2004 CENTER 1600/298											
•	FOREIGN PATENT DOCUMENTS											
	72	DOCUMENT	ļ				TRANSLATION					
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO				
,					İ							
		OTHER DO	OCUMENTS (Including	Author, Title, Date, Pertin	ent Pages, Etc	c.)	· · · · · · · · · · · · · · · · · · ·					
							<del></del>					
			<del></del>									
			<u> </u>				-					
٠												
	EXAMINER			DATE CONSIDERED								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.